Details of the Drug

General Information of Drug (ID: DM78NWP)

Drug Name

Dostarlimab

Indication

Disease Entry	ICD 11	Status	REF
Endometrial cancer	2C76	Approved	[1]
Neoplasm	2A00-2F9Z	Phase 3	[2]
Breast cancer	2C60-2C65	Phase 2	[3]
Multiple myeloma	2A83	Phase 2	[4]

Affected Organisms

Humans and other mammals

ATC Code

L01FF07: Dostarlimab

L01FF: PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors

L01F: MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES

L01: ANTINEOPLASTIC AGENTS

L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Drug Type

Antibody

Sequence

>heavy chain
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVSTISGGGSYTYY
QDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASPYYAMDYWGQGTTVTVSSASTK
GPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS
LSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFP
PKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVS
VLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVS
LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFS
CSVMHEALHNHYTQKSLSLSLGK
>light chain
DIQLTQSPSFLSAYVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASTLHTGVPS
RFSGSGSGTEFTLTISSLQPEDFATYYCQHYSSYPWTFGQGTKLEIKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 35,730 mgh/L [5]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 171 mg/L [5]
Clearance: The clearance of drug is 0.007 L/h [5]
Half-life: The concentration or amount of drug in body reduced by one-half in 25.4 days [5]
Metabolism: The drug is metabolized via the catabolic pathways into smaller peptides and amino acids [5]
Vd: The volume of distribution (Vd) of drug is 5.3 L [5]

Cross-matching ID

UNII: P0GVQ9A4S5
DrugBank ID: DB15627
TTD ID: DGQU43

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Programmed cell death protein 1 (PD-1)	TTNBFWK	PDCD1_HUMAN	Inhibitor	[6]

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Endometrial cancer

ICD Disease Classification

2C76

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Programmed cell death protein 1 (PD-1)	DTT	PDCD1	7.26E-01	-0.01	-0.03

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
2	ClinicalTrials.gov (NCT03981796) A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer (RUBY). U.S. National Institutes of Health.
3	ClinicalTrials.gov (NCT04837209) Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer (NADiR). U.S. National Institutes of Health.
4	ClinicalTrials.gov (NCT04126200) Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 5). U.S. National Institutes of Health.
5	FDA Approved Drug Products: Jemperli (dostarlimab-gxly) for intravenous injection
6	Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer. Future Oncol. 2021 Mar;17(8):877-892.